OncoMatch/Clinical Trials/NCT06878625
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Is NCT06878625 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Sacituzumab Govitecan combined with Toripalimab and Sacituzumab govitecan combined with anti-angiogenesis for evaluating the efficacy of trop-2 adc combination therapy in advanced triple-negative breast cancer.
Treatment: Sacituzumab Govitecan combined with Toripalimab · Sacituzumab govitecan combined with anti-angiogenesis — Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) the efficacy and safety. Indications: Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) treat above 2 late three negative breast cancer (TNBC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression < 10% (< 10%)
immunohistochemical detection of ER < 10%
Required: PR (PGR) expression < 10% (< 10%)
immunohistochemical detection of PR < 10%
Required: HER2 (ERBB2) 0-1+ by IHC or 2+ with negative FISH or CISH (0-1+ by IHC or 2+ with negative FISH or CISH)
HER2 0-1+ or HER2 2+ with negative FISH or CISH results
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: chemotherapy — advanced treatment phase
patients received at least one but no more than two lines of chemotherapy in the advanced treatment phase
Cannot have received: immunotherapy
No prior use of immunotherapy
Cannot have received: anti-angiogenic drug
No prior use of anti-angiogenic drugs
Lab requirements
Blood counts
hemoglobin ≥90 g/l without transfusion within 14 days; absolute neutrophil count (anc) ≥1.5×10^9/l; platelets ≥75×10^9/l
Kidney function
serum creatinine ≤1×uln
Liver function
total bilirubin ≤1.5×uln; ast and alt ≤3×uln (≤5×uln if liver metastasis present)
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06878625 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, anti-angiogenic drug disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 expression < 10% is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR expression < 10% is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 0-1+ by IHC or 2+ with negative FISH or CISH is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify